LSD

Template:Short description Template:Cs1 config Template:Redirect-distinguish {{#invoke:other uses|otheruses}} Template:Use mdy dates Template:Main other {{#invoke:Infobox|infobox}}Template:Template other{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= biosimilars= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= container_only= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= DTXSID= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= class6= component1= component2= component3= component4= component5= component6= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= image_class= image_class2= image_classL= image_classR= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_AU_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= DTXSID2= QID= QID2=PLLR= pregnancy_US= pregnancy_US_comment= |cat=Pages using infobox drug with unknown parameters |format=0|errNS=0

|preview=

}}{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = Lysergic acid diethylamide | INN = Lysergide | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals={{#invoke:ParameterCount |main |component1 |component2 |component3 |component4|component5|component6 }} | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=202531CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4c3c(ccc4)C2=C1)C1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1VAYOSLLFUXYJDT-RDTXWAMCSA-NTemplate:StdinchiciteTemplate:Stdinchicite808567.02<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> | _combo_data= | _physiological_data= | _clinical_data=ReferenceNone<ref name="NHM-MDMA"/>Low<ref>Template:Cite book</ref> CBy mouth, sublingualDelysidSerotonin receptor agonist; Serotonin 5-HT_2A receptor agonist; Serotonergic psychedelic; HallucinogenNone | _legal_data=Schedule 9F2Schedule IIIAnlage IClass AClass AP ISchedule IIllicit drug

| _other_data=(6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide

| _image_0_or_2 = LSD skeletal formula.svgLSD-from-xtal-and-Spartan-PM3-3D-balls-web.png | _image_LR =

| _datapage = LSD (data page) | _vaccine_target={{#ifeq: | vaccine | | _type_not_vaccine }} | _legal_all=Schedule 9F2Schedule IIIClass ASchedule IP IIllicit drug | _ATC_prefix_supplemental=None | _has_EMA_link = | CAS_number=50-37-3 | PubChem=5761 | ChemSpiderID=5558 | ChEBI=6605 | ChEMBL=263881 | DrugBank=DB04829 | KEGG=C07542 | _hasInChI_or_Key={{#if:1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1VAYOSLLFUXYJDT-RDTXWAMCSA-N |yes}} | UNII=8NA5SWF92O | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs={{#invoke:ParameterCount |main |CAS_number2 |ATC_prefix2 |PubChem2 |PubChemStructure2 |IUPHAR_ligand2 |DrugBank2 |ChemSpiderID2 |UNII2 |KEGG2 |ChEBI2 |ChEMBL2 |PDB_ligand2 |NIAID_ChemDB2 |SMILES2 |smiles2 |StdInChI2 |StdInChIKey2 |DTXCID2}} | _countIndexlabels={{#invoke:ParameterCount |main |index_label |index2_label}} | _trackListSortletter= |QID = |QID2 = |Verifiedfields= |Watchedfields=changed |verifiedrevid=629704081}}

Lysergic acid diethylamide, commonly known as LSD (from German {{#invoke:Lang|lang}}; often referred to as acid or lucy), is a semisynthetic, non-addictive hallucinogenic compound derived from ergot, known for its powerful psychological effects and serotonergic activity.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It was historically significant in psychiatry and 1960s counterculture; it is currently legally restricted but experiencing renewed scientific interest and increasing use.

When taken orally, LSD has an onset of action within 0.4 to 1.0 hours (range: 0.1–1.8 hours) and a duration of effect lasting 7 to 12 hours (range: 4–22 hours).<ref name="HolzeSinghLiechti2024" /><ref name="PassieHalpernStrichtenoth2008" /> It is commonly administered via tabs of blotter paper.<ref name="NIH2016">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> LSD is extremely potent, with noticeable effects at doses as low as 20 micrograms and is sometimes taken in much smaller amounts for microdosing. Yet no fatal human overdoses have been documented. LSD is mainly used recreationally or for spiritual purposes.<ref name="EU2018">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite news</ref> LSD can cause mystical experiences.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref> LSD exerts its effects primarily through high-affinity binding to several serotonin receptors, especially 5-HT_2A, and to a lesser extent dopaminergic and adrenergic receptors. LSD reduces oscillatory power in the brain’s default mode network and flattens brain hierarchy.<ref name="Nichols2016">Template:Cite journal</ref><ref>Template:Cite journal</ref> At higher doses, it can induce visual and auditory hallucinations, ego dissolution, and anxiety.<ref name="LeptourgosFortier-Davy2020">Template:Cite journal</ref><ref name=":3">Template:Cite journal</ref> LSD use can cause adverse psychological effects such as paranoia and delusions and may lead to persistent visual disturbances known as hallucinogen persisting perception disorder (HPPD).

Swiss chemist Albert Hofmann first synthesized LSD in 1938 and discovered its powerful psychedelic effects in 1943 after accidental ingestion. It became widely studied in the 1950s and 1960s.<ref name="EU2018" /><ref name="NIH2018C">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It was initially explored for psychiatric use due to its structural similarity to serotonin and safety profile.<ref name="Nichols2018a">Template:Cite journal</ref> It was used experimentally in psychiatry for treating alcoholism and schizophrenia.<ref name="Use of d-lysergic acid diethylamide">Template:Cite journal</ref> By the mid-1960s, LSD became central to the youth counterculture in places like San Francisco and London, influencing art, music, and social movements through events like Acid Tests and figures such as Owsley Stanley and Michael Hollingshead. Its psychedelic effects inspired distinct visual art styles, music innovations, and caused a lasting cultural impact. However, its association with the counterculture movement of the 1960s led to its classification as a Schedule I drug in the U.S. in 1968.<ref>Template:Cite book</ref> It was also listed as a Schedule I controlled substance by the United Nations in 1971 and remains without approved medical uses.<ref name="EU2018" />

Despite its legal restrictions, LSD remains influential in scientific and cultural contexts. Research on LSD declined due to cultural controversies by the 1960s, but has resurged since 2009. In 2024, the United States Food and Drug Administration designated a form of LSD a breakthrough therapy for generalized anxiety disorder. As of 2017, about 10% of people in the U.S. had used LSD at some point, with 0.7% having used it in the past year.<ref name="NIH2018B">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Usage rates have risen, with a 56.4% increase in adult use in the U.S. from 2015 to 2018.<ref>Template:Cite journal</ref>

Uses

Recreational

LSD is commonly used as a recreational drug for its psychedelic effects.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Spiritual

LSD can catalyze intense spiritual experiences and is thus considered an entheogen. Some users have reported out of body experiences. In 1966, Timothy Leary established the League for Spiritual Discovery with LSD as its sacrament.<ref>Template:Cite book</ref><ref>San Francisco Chronicle September 20, 1966 Page One</ref> Stanislav Grof has written that religious and mystical experiences observed during LSD sessions appear similar to descriptions in sacred scriptures of great religions of the world and the texts of ancient civilizations.<ref name="Grof1979">Template:Cite book</ref>

Medical

LSD currently has no approved uses in medicine.<ref name=Nutt2009>Template:Cite journal</ref><ref>Template:Cite news</ref> A meta analysis concluded that a single dose was shown to be effective at reducing alcohol consumption in people suffering from alcoholism.<ref name="Lysergic acid diethylamide LSD fo"/> LSD has also been studied in depression, anxiety,<ref name=":5">Template:Cite news</ref><ref name=":6">Template:Cite journal</ref> and drug dependence, with positive preliminary results.<ref>Template:Cite journal</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Dosage

File:5 LSD blotters.png

A "five strip" of LSD blotters

LSD is an extraordinarily potent substance,<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022">Template:Cite book</ref><ref name="Nichols2018a" /><ref name="Nichols2018b">Template:Cite book</ref> and is one of the most potent psychoactive drugs known.<ref name="Nichols2018a" /><ref name="Nichols2018b" /> This means that it produces its pharmacological effects at very small doses, with its dose range measured in micrograms (μg); that is, millionths of a gram.<ref name="HolzeSinghLiechti2024" /><ref name="Nichols2018a" /> Noticeable effects can occur with doses of LSD as low as 20Template:Nbspμg, which is around 1/200th the mass of a grain of sand.<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022" /><ref name="Nichols2018a" /><ref name="EU2018" /> LSD is approximately 200Template:Nbsptimes as potent as psilocybin and 5,000Template:Nbsptimes as potent as mescaline, meaning that it produces effects of similar magnitude at 1/200 and 1/5,000 times the respective doses.<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022" /><ref name="Hofmann1968">Template:Cite book</ref>

The usual dose range of LSD for psychedelic effects is 20 to 200Template:Nbspμg.<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022" /> The typical intermediate and "good effect" dose for a psychedelic experience is 100Template:Nbspμg (range 75–150Template:Nbspμg, while 20 to 50Template:Nbspμg is a low or "minidose" and 200Template:Nbspμg is a high or ego-dissolution dose.<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022" /><ref name="PassieHalpernStrichtenoth2008">Template:Cite journal</ref> A dose range as wide as 10 to 400Template:Nbspμg has been reported.<ref name="LuethiLiechti2018">Template:Cite journal</ref> LSD may also be used in microdosing.<ref name="PolitoStevenson2019">Template:Cite journal</ref> In this context, it may be used at subthreshold or microdoses of less than 10Template:Nbspμg.<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022" />

The doses of LSD present in illicit LSD samples have decreased over time. In the mid-1960s, Owsley Stanley, the most important black market LSD manufacturer in the United States, distributed LSD at a standard concentration of 270Template:Nbspμg,<ref name="LSD Samples Analysis">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> while street samples of the 1970s contained 30 to 300Template:Nbspμg. By the 1980s, the amount had reduced to between 100 and 125Template:Nbspμg, dropping more in the 1990s to the 20 to 80Template:Nbspμg range,<ref name="henderson-glass">Template:Cite book</ref> and even further in the 2000s.<ref name="LSD Samples Analysis" /><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Effects

LSD produces a variety of physical, psychological, and sensory effects.<ref name="HolzeSinghLiechti2024" />

Psychological

The primary immediate psychological effects of LSD are visual pseudo-hallucinations and altered thought, often referred to as "trips". These sensory alterations are considered pseudohallucinations because the subject does not perceive the patterns seen as being located in three-dimensional space outside the body.<ref>Template:Cite journal</ref> LSD is not considered addictive. These effects typically begin within 20–30 minutes of oral ingestion, peak three to four hours after ingestion, and can last up to 20 hours, particularly with higher doses. An "afterglow" effect, characterized by an improved mood or perceived mental state, may persist for days or weeks following ingestion.<ref>Template:Cite journal</ref> Positive experiences, or "good trips", are described as intensely pleasurable and can include feelings of joy, euphoria, an increased appreciation for life, decreased anxiety, a sense of spiritual enlightenment, and a feeling of interconnectedness with the universe.<ref name="erowid-faq">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="PMID6054248">Template:Cite journal</ref>

Negative experiences, commonly known as "bad trips", can induce feelings of fear, agitation, anxiety, panic, and paranoia.<ref name="PassieHalpernStrichtenoth2008" /><ref name="kopra_adverse">Template:Cite journal</ref> While the occurrence of a bad trip is unpredictable, factors such as mood, surroundings, sleep, hydration, and social setting, collectively referred to as "set and setting", can influence the risk and are considered important in minimizing the likelihood of a negative experience.<ref name=MedlinePlus>Template:Citation</ref><ref name=CESAR>Template:Citation</ref>

Sensory

LSD induces an animated sensory experience affecting senses, emotions, memories, time, and awareness. The effects range from subtle perceptual changes to profound cognitive shifts. Alterations in auditory and visual perception are common.<ref name="linton-langs"/><ref>Template:Cite journal</ref>

Users may experience enhanced visual phenomena, such as vibrant colors, objects appearing to morph, ripple or move, and geometric patterns on various surfaces. Changes in the perception of food's texture and taste are also noted, sometimes leading to aversion towards certain foods.<ref name="linton-langs">Template:Cite journal</ref><ref>Template:Cite journal</ref>

There are reports of inanimate objects appearing animated, with static objects seeming to move in additional spatial dimensions.<ref>Template:Cite journal</ref> The auditory effects of LSD may include echo-like distortions of sounds, and an intensified experience of music. Basic visual effects often resemble phosphenes and can be influenced by concentration, thoughts, emotions, or music.<ref>Template:Cite journal</ref> Higher doses can lead to more intense sensory perception alterations, including synesthesia, perception of additional dimensions, and temporary dissociation.

Physical

File:Possible physical effects of lysergic acid diethylamide (LSD).svg

CitationClass=web }}</ref><ref name=Schiff>Template:Cite journal</ref>

File:Mydriasis due to LSD usage.jpg

Patient with mydriasis (pupil dilation) due to usage of LSD.

LSD can induce physical effects such as pupil dilation, decreased appetite, increased sweating, and wakefulness. The physical reactions to LSD vary greatly and some may be a result of its psychological effects. Commonly observed symptoms include increased body temperature, blood sugar, and heart rate, as well as goose bumps, jaw clenching, dry mouth, and hyperreflexia. In cases of adverse reactions, users may experience numbness, weakness, nausea, and tremors.<ref name="EU2018" />

Onset and duration

The psychoactive effects of LSD last on average between 7 and 11Template:Nbsphours, with a possible range of 4 to 22Template:Nbsphours.<ref name="HolzeSinghLiechti2024" /> Higher doses tend to lead to a longer duration of action.<ref name="HolzeSinghLiechti2024" /> The onset of action when administered orally is 0.4 to 1.0Template:Nbsphours on average, with a possible range of 0.1 to 1.8Template:Nbsphours.<ref name="HolzeSinghLiechti2024" />

Adverse effects

File:HarmCausedByDrugsTable.svg

Table from the 2010 ISCD study ranking various drugs (legal and illegal) based on statements by drug-harm experts. LSD was found to be the 18th most dangerous out of 20 considered.<ref name="Nutt_2010">Template:Cite journal</ref>

File:Possible physical effects of lysergic acid diethylamide (LSD).svg

Possible physical effects of LSD

File:Rational harm assessment of drugs radar plot.svg

Addiction experts in psychiatry, chemistry, pharmacology, forensic science, epidemiology, and the police and legal services engaged in delphic analysis regarding 20 popular recreational drugs. LSD was ranked 14th in dependence, 15th in physical harm, and 13th in social harm.<ref>Template:Cite journal</ref>

LSD, a classical psychedelic, is deemed physiologically safe at standard dosages (50–200 μg) and its primary risks lie in psychological effects rather than physiological harm.<ref name="pmid14761703">Template:Cite journal</ref><ref name="pmid29408722">Template:Cite journal</ref> A 2010 study by David Nutt ranked LSD as significantly less harmful than alcohol, placing it near the bottom of a list assessing the harm of 20 drugs.<ref name="pmid21036393">Template:Cite journal</ref>

Psychological effects

Mental disorders

LSD can induce panic attacks or extreme anxiety, colloquially termed a "bad trip". Despite lower rates of depression and substance abuse found in psychedelic drug users compared to controls, LSD presents heightened risks for individuals with severe mental illnesses like schizophrenia.<ref>Template:Cite journal</ref><ref name="Murray">Template:Citation</ref> These hallucinogens can catalyze psychiatric disorders in predisposed individuals, although they do not tend to induce illness in emotionally healthy people.<ref name="pmid14761703"/>

Suggestibility

While research from the 1960s indicated increased suggestibility under the influence of LSD among both mentally ill and healthy individuals, recent documents suggest that the CIA and Department of Defense have discontinued research into LSD as a means of mind control.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>Template:Primary source inline

Flashbacks

Flashbacks are psychological episodes where individuals re-experience some of LSD's subjective effects after the drug has worn off, persisting for days or months post-hallucinogen use.<ref name="Halpern2003">Template:Cite journal</ref><ref>Template:Cite journal</ref> These experiences are associated with hallucinogen persisting perception disorder (HPPD), where flashbacks occur intermittently or chronically, causing distress or functional impairment.<ref name="Halpern2018">Template:Cite book</ref>

The etiology of flashbacks is varied. Some cases are attributed to somatic symptom disorder, where individuals fixate on normal somatic experiences previously unnoticed prior to drug consumption.<ref>Template:Cite journal</ref> Other instances are linked to associative reactions to contextual cues, similar to responses observed in individuals with past trauma or emotional experiences.<ref>Template:Cite book</ref> The risk factors for flashbacks remain unclear, but pre-existing psychopathologies may be significant contributors.<ref>Template:Cite journal</ref>

Estimating the prevalence of HPPD is challenging. It is considered rare, with occurrences ranging from 1 in 20 users experiencing the transient and less severe type 1 HPPD, to 1 in 50,000 for the more concerning type 2 HPPD.<ref name="Halpern2018"/> Contrary to internet rumors, LSD is not stored long-term in the spinal cord or other parts of the body. Pharmacological evidence indicates LSD has a half-life of 175 minutes and is metabolized into water-soluble compounds like 2-oxo-3-hydroxy-LSD, eliminated through urine without evidence of long-term storage.<ref name="PassieHalpernStrichtenoth2008" /> Clinical evidence also suggests that chronic use of SSRIs can potentiate LSD-induced flashbacks, even months after stopping LSD use.<ref name="drug-interaction">Template:Cite book</ref>Template:Rp

Tolerance

LSD shows significant tachyphylaxis, with tolerance developing 24 hours after administration. The progression of tolerance at intervals shorter than 24 hours remains largely unknown.<ref>Template:Cite book</ref> Tolerance typically resets to baseline after 3–4 days of abstinence.<ref name="pmid28701958">Template:Cite journal</ref><ref>Template:Cite journal</ref> Significant cross-tolerance occurs between LSD, mescaline and psilocybin.<ref name="isbell_mescaline">Template:Cite journal</ref><ref name="isbell_psilocybin">Template:Cite journal</ref> A slight cross-tolerance to DMT is observed in humans highly tolerant to LSD.<ref>Template:Cite journal</ref> Tolerance to LSD also builds up with consistent use,<ref name="springer">Template:Cite journal</ref> and is believed to result from serotonin 5-HT_2A receptor downregulation.<ref name="pmid28701958" /> Researchers believe that tolerance returns to baseline after two weeks of not using psychedelics.<ref name=lsdtol>Template:Cite journal</ref>

Addiction and dependence liability

LSD is widely considered to be non-addictive, despite its potential for abuse.<ref name="NHM-MDMA">Template:Cite book</ref><ref name="pmid14761703"/><ref name="Lus2006">Template:Cite journal</ref><ref name="clinicalLSD"/> Attempts to train laboratory animals to self-administer LSD have been largely unsuccessful.<ref name="pmid14761703"/> Although tolerance to LSD builds up rapidly, a withdrawal syndrome does not appear, suggesting that a potential syndrome does not necessarily relate to the possibility of acquiring rapid tolerance to a substance.<ref>Template:Cite journal</ref> A report examining substance use disorder for DSM-IV noted that almost no hallucinogens produced dependence, unlike psychoactive drugs of other classes such as stimulants and depressants.<ref name="pmid29366418">Template:Cite journal</ref><ref>Template:Cite journal</ref>

Cancer and pregnancy

The mutagenic potential of LSD is unclear. Overall, the evidence seems to point to limited or no effect at commonly used doses.<ref>Template:Cite journal</ref> Studies showed no evidence of teratogenic or mutagenic effects.<ref name="PassieHalpernStrichtenoth2008" />

Long-term effects

A potential risk of frequent repeated long-term use of LSD and other serotonergic psychedelics is cardiac fibrosis and valvulopathy due to serotonin 5-HT_2B receptor agonism.<ref name="TagenMantuanivanHeerden2023">Template:Cite journal</ref><ref name="RouaudCalderHasler2024">Template:Cite journal</ref><ref name="NahlawiPtaszekRuskin2025">Template:Cite journal</ref><ref name="Wsół2023">Template:Cite journal</ref><ref name="McIntyre2023">Template:Cite journal</ref> This may also be the case with microdosing.<ref name="TagenMantuanivanHeerden2023" /><ref name="RouaudCalderHasler2024" /><ref name="NahlawiPtaszekRuskin2025" /> However, the risks are theoretical, and more research is needed to see if these complications can actually occur with psychedelics.<ref name="TagenMantuanivanHeerden2023" /><ref name="Wsół2023" /> A preliminary animal study found that chronic microdosing of LSD did not result in heart structure changes or valvulopathy in rodents.<ref name="EffingerKingCalderon2024">Template:Cite journal</ref> Research appears to be mixed on whether LSD is a potent serotonin 5-HT_2B receptor agonist or not, with some studies finding it to be essentially inactive.<ref name="LuethiLiecthi2021">Template:Cite book</ref>

Interactions

Some psychedelics, including LSD, are metabolized by the cytochrome P450 enzyme CYP2D6. Concurrent use of selective serotonin reuptake inhibitors (SSRIs), some of which are potent inhibitors of CYP2D6, with LSD may heighten the risk of serotonin syndrome.<ref name="drug-interaction"/>Template:Rp Chronic usage of SSRIs, tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) is believed to diminish the subjective effects of psychedelics, likely due to 5-HT_2A receptor downregulation or desensitization induced by elevated serotonin levels.<ref name="PassieHalpernStrichtenoth2008" /><ref name="drug-interaction"/>Template:Rp Contrary to the preceding notions however, a clinical study found that administration of LSD to people taking paroxetine, an SSRI and strong CYP2D6 inhibitor, increased LSD exposure by about 1.5-fold, was well-tolerated, and did not modify the pleasant subjective effects or physiological effects of LSD, whereas negative effects of LSD, including "bad drug effect", anxiety, and nausea, were reduced.<ref name="BeckerHumbert-DrozMueller2025">Template:Cite journal</ref> Similarly, a clinical study with LSD found that LSD levels were 75% higher in people with non-functional CYP2D6 (poor metabolizers) compared to those with functional CYP2D6.<ref name="HalmanKongSarris2024">Template:Cite journal</ref><ref name="VizeliStraumannHolze2021">Template:Cite journal</ref> In contrast to certain other psychedelics, MAOIs do not inhibit the metabolism of or potentiate the effects of LSD and instead reduce its effects.<ref name="PassieHalpernStrichtenoth2008" /> Interactions between psychedelics and antipsychotics or anticonvulsants are not well-documented; however, co-use with mood stabilizers like lithium may induce seizures and dissociative effects, particularly in individuals with bipolar disorder.<ref name="drug-interaction"/>Template:Rp<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref> Lithium notably intensifies LSD reactions, potentially leading to acute comatose states when combined.<ref name="PassieHalpernStrichtenoth2008" />

Overdose

There have been no documented fatal human overdoses from LSD,<ref name="PassieHalpernStrichtenoth2008" /><ref name="Lipow22">Template:Cite journal</ref> although there has been no "comprehensive review since the 1950s" and "almost no legal clinical research since the 1970s".<ref name="PassieHalpernStrichtenoth2008" /> A 5Template:Nbspmg overdose of LSD (50Template:Nbsptimes the usual dose) produced severe nausea and vomiting along with behavioral and emotional disturbances.<ref name="Shulgin1976" /><ref name="ReynoldsPeterson1966">Template:Cite journal</ref> Eight individuals who had accidentally consumed an exceedingly high amount of LSD, mistaking it for cocaine, and had gastric levels of 1,000–7,000Template:Nbspμg/100Template:NbspmL LSD tartrate and blood plasma levels up to 26Template:Nbspμg/mL, had suffered from comatose states, vomiting, respiratory problems, hyperthermia, and light gastrointestinal bleeding; however, all of them survived without residual effects upon hospital intervention.<ref name="PassieHalpernStrichtenoth2008" /><ref>Template:Cite journal</ref>

Individuals experiencing a bad trip after LSD intoxication may present with severe anxiety and tachycardia, often accompanied by phases of psychotic agitation and varying degrees of delusions.<ref name="pmid29408722" /> Cases of death on a bad trip have been reported due to prone maximal restraint (commonly known as a hogtie) and positional asphyxia when the individuals were restrained by law enforcement personnel.<ref name="pmid29408722" />

Massive doses are largely managed by symptomatic treatments, and agitation can be addressed with benzodiazepines.<ref name="Medscape">Template:EMedicine</ref><ref>Template:Cite journal</ref> Reassurance in a calm, safe environment is beneficial.<ref>Template:Cite journal</ref> Antipsychotics such as haloperidol are not recommended as they may have adverse psychotomimetic effects.<ref name="Medscape" /> Gastrointestinal decontamination with activated charcoal is of little use due to the rapid absorption of LSD, unless done within 30–60 minutes of ingesting exceedingly huge amounts.<ref name="Medscape" /> Administration of anticoagulants, vasodilators, and sympatholytics may be useful for treating ergotism.<ref name="Medscape" />

The lethal oral dose of LSD in humans is estimated at 100 mg, based on LD₅₀ and lethal blood concentrations observed in rodent studies.<ref name="pmid29408722" />

Designer drug overdose

Many novel psychoactive substances of 25-NB (NBOMe) series, such as 25I-NBOMe and 25B-NBOMe, are regularly sold as LSD in blotter papers.<ref name="pmid30261175">Template:Cite journal</ref><ref>Template:Cite journal</ref> NBOMe compounds are often associated with life-threatening toxicity and death.<ref name="pmid30261175"/><ref name="pmid35343858">Template:Cite journal</ref> Fatalities involved in NBOMe intoxication suggest that a significant number of individuals ingested the substance which they believed was LSD,<ref name="pmid31915427">Template:Cite journal</ref> and researchers report that "users familiar with LSD may have a false sense of security when ingesting NBOMe inadvertently".<ref name="Lipow22"/> Researchers state that the alleged physiological toxicity of LSD is likely due to psychoactive substances other than LSD.<ref name="pmid29408722"/>

NBOMe compounds are reported to have a bitter taste,<ref name="Lipow22"/> are not active orally,Template:Efn and are usually taken sublingually.<ref name="pmid28097528">Template:Cite book</ref> When NBOMes are administered sublingually, numbness of the tongue and mouth followed by a metallic chemical taste was observed, and researchers describe this physical side effect as one of the main discriminants between NBOMe compounds and LSD.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>Template:Cite book</ref> Despite its high potency, recreational doses of LSD have only produced low incidents of acute toxicity, but NBOMe compounds have extremely different safety profiles.<ref name="Lipow22"/><ref name="pmid35343858"/> Testing with Ehrlich's reagent gives a positive result for LSD and a negative result for NBOMe compounds.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

Pharmacology

Pharmacodynamics

File:LSDaffinities.GIF

Affinities (K_i) of LSD for various receptors. The lower the value, the more strongly LSD binds to that receptor (i.e., with higher affinity). The horizontal line represents an approximate value for human plasma concentrations of LSD, and hence, affinities that are above the line are unlikely to be involved in LSD's effects. Values are averages the K_i Database.<ref name="PDSPKiDatabase" />

Template:Nowrap

Target	Affinity (Ki, nM)
5-HT1A	0.64–7.3 (Ki) 6.4 (Template:Abbrlink) 110% (Template:Abbrlink)
5-HT1B	3.9
5-HT1D	3.9–14
5-HT1E	93
5-HT1F	Template:Abbr
5-HT2A	0.47–21 (Ki) 0.24–538 (Template:Abbr) 23–88% (Template:Abbr)
5-HT2B	0.98–30 (Ki) 0.68–12,000 (Template:Abbr) 13–73% (Template:Abbr)
5-HT2C	1.1–48 (Ki) 0.85–1,590 (Template:Abbr) 26–79% (Template:Abbr)
5-HT3	>10,000
5-HT4	1,000 (rat)
5-HT5A	9.0
5-HT5B	3.2 (rat)
5-HT6	2.3–6.9
5-HT7	6.3–6.6
α1A	670–1,128
α1B	8,677
α1D	Template:Abbr
α2A	12–46
α2B, α2C	Template:Abbr
β1	140–1,601
β2	740–3,461
β3	Template:Abbr
D1	155–340 (Ki) 35–63 (Template:Abbr) 35–44% (Template:Abbr)
D2	61–126
D3	27–60
D4	26–158
D5	75–344
H1	1,100–1,540
H2–H4	Template:Abbr
M1–M5	Template:Abbr
I1	Template:Abbr
σ1, σ2	Template:Abbr
TAAR1	450 (Ki) (rat) 10,000 (Ki) (mouse) 1,400 (Template:Abbr) (rat) 9,700 (Template:Abbr) (mouse) >20,000 (Template:Abbr) (human)
Template:Abbrlink	>30,000 (Ki) >100,000 (Template:Abbrlink)
Template:Abbrlink	5,600–>30,000 (Ki) >100,000 (Template:Abbr)
Template:Abbrlink	>30,000 (Ki) >100,000 (Template:Abbr)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise noted. Refs: <ref name="PDSPKiDatabase">{{#invoke:citation/CS1|citation		CitationClass=web }}</ref><ref name="BindingDB">{{#invoke:citation/CS1|citation	CitationClass=web }}</ref><ref name="HolzeSinghLiechti2024">Template:Cite journal</ref><ref name="Ray2010">Template:Cite journal</ref><ref name="RickliLuethiReinisch2015">Template:Cite journal</ref><ref name="RickliMoningHoener2016">Template:Cite journal</ref><ref name="LuethiTrachselHoener2018">Template:Cite journal</ref><ref name="EshlemanForsterWolfrum2014">Template:Cite journal</ref> <ref name="JanowskyEshlemanJohnson2014">Template:Cite journal</ref><ref name="Wsół2023">Template:Cite journal</ref><ref name="EganGrindeDupre2000">Template:Cite journal</ref><ref name="WackerWangMcCorvy2017">Template:Cite journal</ref><ref name="McCorvy2013">Template:Cite thesis Alt URL</ref><ref name="PorterBenwellLamb1999">Template:Cite journal</ref><ref name="GainetdinovHoenerBerry2018">Template:Cite journal</ref><ref name="SimmlerBuchyChaboz2016">Template:Cite journal</ref>

LSD is a serotonergic psychedelic and acts as a non-selective serotonin receptor modulator.<ref name="Nichols2018a" /> It binds with high affinity to most of the serotonin receptors.<ref name="HolzeSinghLiechti2024" /> The psychedelic effects of LSD are thought to be mediated specifically by activation of the serotonin 5-HT_2A receptor.<ref name="Nichols2018a" /><ref name="HolzeSinghLiechti2024" /> However, a role of other serotonin receptors and targets in the effects of LSD cannot be ruled out and may be considered likely.<ref name="HalberstadtGeyer2011">Template:Cite journal</ref> Uniquely among serotonergic psychedelics, LSD also shows potentially significant affinity for the dopamine receptors, albeit much lower than for most of the serotonin receptors.<ref name="HolzeSinghLiechti2024" /><ref name="Marona-LewickaThistedNichols2005">Template:Cite journal</ref>

LSD binds to most serotonin receptor subtypes except for the serotonin 5-HT₃ and 5-HT₄ receptors.<ref name="HolzeSinghLiechti2024" /> However, some of these serotonin receptors may not be affected at typical brain concentrations of LSD.<ref name="pmid14761703"/> In humans, recreational doses of LSD may affect 5-HT_1A, 5-HT_2A, 5-HT_2B, 5-HT_2C, 5-HT_5A, and 5-HT₆ receptors.<ref name="Aghajanian" /> Although not present in humans, 5-HT_5B receptors found in rodents also have a high affinity for LSD.<ref name="Nelson2004">Template:Cite journal</ref> The psychedelic effects of LSD are attributed to activation of 5-HT_2A receptors.<ref>Template:Cite journal</ref> Many but not all serotonin 5-HT_2A agonists are psychedelics and serotonin 5-HT_2A antagonists block the psychedelic activity of LSD. LSD exhibits functional selectivity at the serotonin 5-HT_2A and 5-HT_2C receptors in that it activates the signal transduction enzyme phospholipase A2 instead of activating the enzyme phospholipase C as the endogenous ligand serotonin does.<ref>Template:Cite journal</ref>

Exactly how LSD produces its effects is unknown, but it is thought that it works by increasing glutamate release in the cerebral cortex<ref name="pmid14761703"/> and therefore excitation in this area, specifically in layer V.<ref>Template:Cite journal</ref> LSD, like many other drugs of recreational use, has been shown to activate DARPP-32-related pathways.<ref>Template:Cite journal</ref> The drug enhances dopamine D₂ receptor protomer recognition and signaling of D₂–5-HT_2A receptor complexes,<ref name="pmid24309097">Template:Cite journal</ref> which may contribute to its psychotropic effects.<ref name="pmid24309097" /> LSD has been shown to have low affinity for H1 receptors, displaying antihistamine effects, although the significance of this at doses used in humans is unknown.<ref>Template:Cite journal</ref><ref name="synth2"/>

LSD is a biased agonist that induces a conformation in serotonin receptors that preferentially recruits β-arrestin over activating G proteins.<ref name="Chen_2017">Template:Cite journal</ref> LSD also has an exceptionally long residence time when bound to serotonin receptors lasting hours, consistent with the long-lasting effects of LSD despite its relatively rapid clearance.<ref name="RothGumpper2023">Template:Cite journal</ref><ref name="Chen_2017" /> A crystal structure of the serotonin 5-HT_2B receptor bound to LSD reveals an extracellular loop that forms a "lid" over the diethylamide end of the binding cavity and "traps" LSD in the binding pocket, which explains the slow rate of LSD unbinding from serotonin receptors.<ref name="RothGumpper2023" /><ref name="WackerWang2017">Template:Cite journal</ref> The related lysergamide lysergic acid amide (LSA) that lacks the diethylamide moiety is far less hallucinogenic in comparison.<ref name="WackerWang2017" /> Moreover, a specific residue in the binding pocket is partially responsible for the prolonged action of LSD, and this residue is found in the human protein but not in the receptors of rodents.<ref name="RothGumpper2023" />

LSD is an extraordinarily potent psychoactive drug and is among the most potent psychedelics known in humans.<ref name="Nichols2018a" /><ref name="Nichols2018b" /> It is unclear why LSD is so potent.<ref name="Nichols2018b" /><ref name="Nichols2001">Template:Cite journal</ref> The affinity and activational potency of LSD at the human serotonin 5-HT_2A receptor in vitro is unremarkable compared to other psychedelics such as DOI and DOB.<ref name="Nichols2018b" /><ref name="Nichols2001" /> It appears that the N,N-diethylamide moiety of LSD fits into a sterically constrained region of the serotonin 5-HT_2A receptor that specifically accommodates this moiety.<ref name="Nichols2018b" /><ref name="GumpperNichols2024" /><ref name="Nichols2001" />

LSD, like other psychedelics, has been found to increase the expression of genes related to synaptic plasticity and hence to have psychoplastogenic effects.<ref>Template:Cite journal</ref> This is in part due to binding to brain-derived neurotrophic factor (BDNF) receptor tropomyosin receptor kinase B (TrkB).<ref>Template:Cite journal</ref>

There appears to be no significant acute tolerance to the subjective effects of LSD.<ref name="Liechti2016">Template:Citation</ref> Hence, its duration appears to be dictated by pharmacokinetics rather than by pharmacodynamics.<ref name="Liechti2016" /> This is in contrast to MDMA, which shows marked acute tolerance and a duration of effects that is shorter than its elimination half-life.<ref name="Liechti2016" />

The cryo-EM structures of the serotonin 5-HT_2A receptor with LSD, as well as with various other psychedelics and serotonin 5-HT_2A receptor agonists, have been solved and published by Bryan L. Roth and colleagues.<ref name="GumpperJainKim2025">Template:Cite journal</ref><ref name="GumpperDiBertoJain2022">Template:Cite conference</ref>

Mechanisms of action

Neuroimaging studies using resting state fMRI recently suggested that LSD changes the cortical functional architecture.<ref name="Singleton SP">Template:Cite journal</ref> These modifications spatially overlap with the distribution of serotoninergic receptors. In particular, increased connectivity and activity were observed in regions with high expression of 5-HT_2A receptor, while a decrease in activity and connectivity was observed in cortical areas that are dense with 5-HT_1A receptor.<ref name="Delli Pizzi S BP:CNNI">Template:Cite journal</ref> Experimental data suggest that subcortical structures, particularly the thalamus, play a synergistic role with the cerebral cortex in mediating the psychedelic experience. LSD, through its binding to cortical 5-HT_2A receptor, may enhance excitatory neurotransmission along frontostriatal projections and, consequently, reduce thalamic filtering of sensory stimuli towards the cortex.<ref name="Delli Pizzi S NeuroImage">Template:Cite journal</ref> This phenomenon appears to selectively involve ventral, intralaminar, and pulvinar nuclei.<ref name="Delli Pizzi S NeuroImage"/>

Pharmacokinetics

The acute effects of LSD normally last between 6 and 12Template:Nbsphours depending on dosage, tolerance, and age.<ref name="tihkal">Template:Cite book</ref><ref name="PassieHalpernStrichtenoth2008" /> Aghajanian and Bing (1964) found LSD had an elimination half-life of only 175 minutes (about 3 hours);<ref name="Aghajanian">Template:Cite journal</ref> however, using more accurate techniques, Papac and Foltz (1990) reported that 1 μg/kg oral LSD given to a single male volunteer had an apparent plasma half-life of 5.1 hours, with a peak plasma concentration of 5 ng/mL at 3 hours post-dose.<ref name="Papac">Template:Cite journal</ref>

The pharmacokinetics of LSD were not properly determined until 2015, which is not surprising for a drug with the kind of low-μg potency that LSD possesses.<ref name=Dol2015 /><ref name=Muc2016 /> In a sample of 16 healthy subjects, a single mid-range 200 μg oral dose of LSD was found to produce mean maximal concentrations of 4.5 ng/mL at a median of 1.5 hours (range 0.5–4 hours) post-administration.<ref name=Dol2015 /><ref name=Muc2016 /> Concentrations of LSD decreased following first-order kinetics with a half-life of 3.6±0.9 hours and a terminal half-life of 8.9±5.9 hours.<ref name=Dol2015 /><ref name=Muc2016 />

The effects of the dose of LSD given lasted for up to 12 hours and were closely correlated with the concentrations of LSD present in circulation over time, with no acute tolerance observed.<ref name="Dol2015" /><ref name="Muc2016" /> Only 1% of the drug was eliminated in urine unchanged, whereas 13% was eliminated as the major metabolite 2-oxo-3-hydroxy-LSD (O-H-LSD) within 24 hours.<ref name="Dol2015" /><ref name="Muc2016" /> O-H-LSD is formed by cytochrome P450 enzymes, although the specific enzymes involved are unknown, and it does not appear to be known whether O-H-LSD is pharmacologically active or not.<ref name="Dol2015" /><ref name="Muc2016" /> The oral bioavailability of LSD was crudely estimated as approximately 71% using previous data on intravenous administration of LSD.<ref name="Dol2015" /><ref name="Muc2016" /> The sample was equally divided between male and female subjects and there were no significant sex differences observed in the pharmacokinetics of LSD.<ref name="Dol2015" /><ref name="Muc2016" /> In a subsequent, higher-quality study, the oral bioavailability of LSD was about 80%.<ref name="Holze_2024">Template:Cite journal</ref>

A large meal before taking LSD has been found to result in circulating levels that were 50% lower than on an empty stomach.<ref name="PassieHalpernStrichtenoth2008" />

It has been said that there is a peculiar 40-minute lag before onset of the psychedelic effects of LSD when it is administered intravenously.<ref name="GumpperNichols2024" /> This has been said to be related to time-dependent interactions of LSD with the serotonin 5-HT_2A receptor.<ref name="GumpperNichols2024" /> However, contradicting the preceding claims, other sources have stated that intravenous injection of LSD results in onset of effects within a few minutes.<ref name="PassieHalpernStrichtenoth2008" /><ref name="Shulgin1980b" /> In addition, intrathecal injection (intraspinal injection) is reported to have a virtually instantaneous onset of action.<ref name="PassieHalpernStrichtenoth2008" /><ref name="Shulgin1980b" /> Doses of LSD are said to be similar by oral and injectable routes, with the exception of intrathecal injection in which the dosage is reduced to about one-third of usual.<ref name="Shulgin1980b" />

Chemistry

File:Lysergide stereoisomers structural formulae v.2.png

The four possible stereoisomers of LSD. Only (+)-LSD is psychoactive.

LSD is a chiral compound with two stereocenters at the carbon atoms C-5 and C-8, so that theoretically four different optical isomers of LSD could exist. LSD, also called (+)-d-LSD,<ref>Template:Cite book</ref> has the absolute configuration (5R,8R). 5S stereoisomers of lysergamides do not exist in nature and are not formed during the synthesis from d-lysergic acid. Retrosynthetically, the C-5 stereocenter could be analysed as having the same configuration of the alpha carbon of the naturally occurring amino acid L-tryptophan, the precursor to all biosynthetic ergoline compounds.

However, LSD and iso-LSD, the two C-8 isomers, rapidly interconvert in the presence of bases, as the alpha proton is acidic and can be deprotonated and reprotonated. Non-psychoactive iso-LSD which has formed during the synthesis can be separated by chromatography and can be isomerized to LSD.

Pure salts of LSD are triboluminescent, emitting small flashes of white light when shaken in the dark.<ref name="tihkal" /> LSD is strongly fluorescent and will glow bluish-white under UV light.

Synthesis

LSD is an ergoline derivative. It is commonly synthesized by reacting diethylamine with an activated form of lysergic acid. Activating reagents include phosphoryl chloride<ref name="synth1">Template:Cite journal</ref> and peptide coupling reagents.<ref name="synth2">Template:Cite journal</ref> Lysergic acid is made by alkaline hydrolysis of lysergamides like ergotamine, a substance usually derived from the ergot fungus on agar plate. Lysergic acid can also be produced synthetically, although these processes are not used in clandestine manufacture due to their low yields and high complexity.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

Albert Hofmann synthesized LSD in the following manner: (1) hydrazinolysis of ergotamine into D- and L-isolysergic acid hydrazide, (2) separation of the enantiomers with di-(p-toluyl)-D-tartaric acid to get D-isolysergic acid hydrazide, (3) enantiomerization into D-lysergic acid hydrazide, (4) substitution with HNO₂ to D-lysergic acid azide and (5) finally substitution with diethylamine to form D-lysergic acid diethylamide.<ref name="Nichols2018a" />

Research

The precursor for LSD, lysergic acid, has been produced by GMO baker's yeast.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }} Journal Reference: Template:Cite journal</ref>

Stability

"LSD," writes the chemist Alexander Shulgin, "is an unusually fragile molecule ... As a salt, in water, cold, and free from air and light exposure, it is stable indefinitely."<ref name="tihkal" />

LSD has two labile protons at the tertiary stereogenic C5 and C8 positions, rendering these centers prone to epimerisation. The C8 proton is more labile due to the electron-withdrawing carboxamide attachment, but the removal of the chiral proton at the C5 position (which was once also an alpha proton of the parent molecule tryptophan) is assisted by the inductively withdrawing nitrogen and pi electron delocalisation with the indole ring.Template:Citation needed

LSD also has enamine-type reactivity because of the electron-donating effects of the indole ring. Because of this, chlorine destroys LSD molecules on contact; even though chlorinated tap water contains only a slight amount of chlorine, the small quantity of compound typical to an LSD solution will likely be eliminated when dissolved in tap water.<ref name="tihkal" /> The double bond between the 8-position and the aromatic ring, being conjugated with the indole ring, is susceptible to nucleophilic attacks by water or alcohol, especially in the presence of UV or other kinds of light. LSD often converts to "lumi-LSD," which is inactive in human beings.<ref name="tihkal" />

A controlled study was undertaken to determine the stability of LSD in pooled urine samples.<ref>Template:Cite journal</ref>

The concentrations of LSD in urine samples were followed over time at various temperatures, in different types of storage containers, at various exposures to different wavelengths of light, and at varying pH values. These studies demonstrated no significant loss in LSD concentration at 25 °C for up to four weeks. After four weeks of incubation, a 30% loss in LSD concentration at 37 °C and up to a 40% at 45 °C were observed. Urine fortified with LSD and stored in amber glass or nontransparent polyethylene containers showed no change in concentration under any light conditions. The stability of LSD in transparent containers under light was dependent on the distance between the light source and the samples, the wavelength of light, exposure time, and the intensity of light. After prolonged exposure to heat in alkaline pH conditions, 10 to 15% of the parent LSD epimerized to iso-LSD. Under acidic conditions, less than 5% of the LSD was converted to iso-LSD. It was also demonstrated that trace amounts of metal ions in the buffer or urine could catalyze the decomposition of LSD and that this process can be avoided by the addition of EDTA.

Detection

File:LSD Ehrlich reagent test.jpg

CitationClass=web }}</ref>

LSD can be detected in concentrations larger than approximately 10% in a sample using Ehrlich's reagent and Hofmann's reagent. However, detecting LSD in human tissues is more challenging due to its active dosage being significantly lower (in micrograms) compared to most other drugs (in milligrams).<ref name="ReferenceA">Template:Cite journal</ref>

LSD may be quantified in urine for drug testing programs, in plasma or serum to confirm poisoning in hospitalized victims, or in whole blood for forensic investigations. The parent drug and its major metabolite are unstable in biofluids when exposed to light, heat, or alkaline conditions, necessitating protection from light, low-temperature storage, and quick analysis to minimize losses.<ref>R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 12th edition, Biomedical Publications, Foster City, CA, 2020, pp. 1197–1199.</ref> Maximum plasma concentrations are typically observed 1.4 to 1.5 hours after oral administration of 100 μg and 200 μg, respectively, with a plasma half-life of approximately 2.6 hours (ranging from 2.2 to 3.4 hours among test subjects).<ref>Template:Cite journal</ref>

Due to its potency in microgram quantities, LSD is often not included in standard pre-employment urine or hair analyses.<ref name="ReferenceA"/><ref name="pmid36753839">Template:Cite journal</ref> However, advanced liquid chromatography–mass spectrometry methods can detect LSD in biological samples even after a single use.<ref name="pmid36753839"/>

Analogues

{{#invoke:Labelled list hatnote|labelledList|Main article|Main articles|Main page|Main pages}}

A variety of LSD analogues are known.<ref name="Shulgin2003">Template:Cite book</ref><ref name="JacobShulgin1994">Template:Cite journal</ref><ref name="Shulgin1982">Template:Cite book</ref><ref name="Shulgin1980">Template:Cite book</ref><ref name="TiHKAL">Template:CiteTiHKAL</ref> Many of them retain psychedelic effects similarly to LSD, although most have reduced potency and none are notably more potent than LSD.<ref name="Shulgin2003" /><ref name="JacobShulgin1994" /><ref name="Shulgin1982" /><ref name="Shulgin1980" /><ref name="Mangner1978">Template:Cite thesis</ref> Examples include ergine (lysergic acid amide; LSA), ergonovine (ergometrine), methylergonovine (methylergometrine), methysergide, ETH-LAD, AL-LAD, 1-methyl-LSD (MLD-41), and LA-SS-Az (LSZ), among many others.<ref name="Shulgin2003" /><ref name="RutschmannStadler1978">Template:Cite book</ref><ref name="Fanchamps1978">Template:Cite book</ref> Presumed or known prodrugs of LSD, including 1A-LSD (ALD-52), 1P-LSD, and 1V-LSD, have been developed or encountered.<ref name="SchifanoVentoScherbaum2023">Template:Cite journal</ref><ref name="Ponce2024">Template:Cite journal</ref> Some non-hallucinogenic LSD analogues, such as lisuride and 2-bromo-LSD (BOL-148), are known as well.<ref name="GumpperNichols2024">Template:Cite journal</ref><ref name="PfaffHuangMarona-Lewicka1994" /><ref name="Nichols2012">Template:Cite journal</ref> They are lower-efficacy serotonin 5-HT_2A receptor partial agonists and can notably act as hallucinogen antagonists against LSD.<ref name="PfaffHuangMarona-Lewicka1994">Template:Cite journal</ref><ref name="Nichols2012" /> In addition to lysergamide derivatives, simplified or "partial" LSD analogues, such as NDTDI, N-DEAOP-NMT, and DEIMDHPCA, are known.<ref name="Shulgin1976">Template:Cite book</ref><ref name="Nichols1973">Template:Cite thesis</ref><ref name="CampaigneKnapp1971">Template:Cite journal</ref><ref name="WO2021076572">Template:Cite patent</ref> A notable bioisostere of LSD is JRT, the isotryptamine analogue of LSD and a psychedelic and psychoplastogen under investigation to treat schizophrenia.<ref name="TuckDunlapKhatib2025">Template:Cite journal</ref><ref name="Dunlap2022">Template:Cite thesis</ref>

History

{{#invoke:Labelled list hatnote|labelledList|Main article|Main articles|Main page|Main pages}}

Swiss chemist Albert Hofmann first synthesized LSD in 1938 from lysergic acid, a chemical derived from the hydrolysis of ergotamine, an alkaloid found in ergot, a fungus that infects grain.<ref name="EU2018" /><ref name="NIH2018C">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> LSD was the 25th of various lysergamides Hofmann synthesized from lysergic acid while trying to develop a new analeptic, hence the alternate name LSD-25. Hofmann discovered its effects in humans on April 16, in 1943, after unintentionally ingesting an unknown amount, possibly absorbing it through his skin.<ref name="Hofmann2009">Template:Cite book</ref><ref name="Lee1992">Template:Cite book</ref><ref name="Ettinger2017">Template:Cite book</ref> On April 19, 1943, Hofmann intentionaly ingested 0.25 milligrams (250 micrograms) of LSD.<ref>Template:Cite magazine</ref> LSD was first published in the scientific literature by Hofmann and his colleague psychiatrist Werner Stoll in 1943 and the hallucinogenic effects of LSD were first published by Stoll in 1947.<ref name="Gach2008">Template:Cite book</ref><ref name="Horowitz1976">Template:Cite magazine</ref><ref name="StollHofmann1943">Template:Cite journal</ref><ref name="Stoll1947">Template:Cite journal</ref><ref name="Stoll1949">Template:Cite journal</ref>

LSD was subject to exceptional interest within the field of psychiatry in the 1950s and early 1960s, with Sandoz distributing LSD to researchers under the trademark name Delysid in an attempt to find a marketable use for it.<ref name="Lee1992" /> During this period, LSD was controversially administered to hospitalised schizophrenic autistic children, with varying degrees of therapeutic success.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

LSD-assisted psychotherapy was used in the 1950s and early 1960s by psychiatrists such as Humphry Osmond, who pioneered the application of LSD to the treatment of alcoholism, with promising results.<ref name="Lee1992"/><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="Use of d-lysergic acid diethylamide">Template:Cite journal</ref><ref name="Lysergic acid diethylamide LSD fo">Template:Cite journal</ref> Osmond coined the term "psychedelic" (mind manifesting) as a term for LSD and related hallucinogens, superseding the previously held "psychotomimetic" model in which LSD was believed to mimic schizophrenia. In contrast to schizophrenia, LSD can induce transcendent experiences, or mental states that transcend the experience of everyday consciousness, with lasting psychological benefit.<ref name="Nichols2016" /><ref name="Lee1992" /> During this time, the Central Intelligence Agency (CIA) began using LSD in the research project Project MKUltra, which used psychoactive substances to aid interrogation. The CIA administered LSD to unwitting test subjects to observe how they would react, the most well-known example of this being Operation Midnight Climax.<ref name="Lee1992" /> LSD was one of several psychoactive substances evaluated by the U.S. Army Chemical Corps as possible non-lethal incapacitants in the Edgewood Arsenal human experiments.<ref name="Lee1992" />

According to declassified CIA documents, it's possible that the american agency spread LSD on civilians in Europe in the 50s.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite news</ref>

In the 1960s, LSD and other psychedelics were adopted by and became synonymous with the counterculture movement due to their perceived ability to expand consciousness. This resulted in LSD being viewed as a cultural threat to American values and the Vietnam War effort, and it was designated as a Schedule I (illegal for medical as well as recreational use) substance in 1968.<ref>Template:Cite book</ref> It was listed as a Schedule I controlled substance by the United Nations in 1971 and currently has no approved medical uses.<ref name="EU2018" /> Template:As of, about 10% of people in the United States have used LSD at some point in their lives, while 0.7% have used it in the last year.<ref name="NIH2018B">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It was most popular in the 1960s to 1980s.<ref name="EU2018" /> The use of LSD among US adults increased by 56.4% from 2015 to 2018.<ref>Template:Cite journal</ref>

LSD was first synthesized on November 16, 1938<ref>Template:Cite journal</ref> by Swiss chemist Albert Hofmann at the Sandoz Laboratories in Basel, Switzerland as part of a large research program searching for medically useful ergot alkaloid derivatives. The abbreviation "LSD" is from the German "Lysergsäurediethylamid".<ref>Template:Cite book</ref>

File:Albert Hofmann.jpg

Albert Hofmann in 2006.

LSD's psychedelic properties were discovered 5 years later when Hofmann himself accidentally ingested an unknown quantity of the chemical.<ref name="hyponichols">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> The first intentional ingestion of LSD occurred on April 19, 1943,<ref name="hofmann1980" /> when Hofmann ingested 250 μg of LSD. He said this would be a threshold dose based on the dosages of other ergot alkaloids. Hofmann found the effects to be much stronger than he anticipated.<ref name="histlsd">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Sandoz Laboratories introduced LSD as a psychiatric drug in 1947 and marketed LSD as a psychiatric panacea, hailing it "as a cure for everything from schizophrenia to criminal behavior, 'sexual perversions', and alcoholism."<ref name="LSD: The Drug">Template:Cite report</ref> Sandoz would send the drug for free to researchers investigating its effects.<ref name="Hofmann2009"/>

File:Effects of Lysergic Acid Diethylamide (LSD) on Troops Marching.webm

'Effects of Lysergic Acid Diethylamide (LSD) on Troops Marching' – 16mm film produced by the United States military circa 1958

Beginning in the 1950s, the US Central Intelligence Agency (CIA) began a research program code-named Project MKUltra.<ref>Template:Cite book</ref> The CIA introduced LSD to the United States, purchasing the entire world's supply for $240,000 and propagating the LSD through CIA front organizations to American hospitals, clinics, prisons, and research centers.<ref>Template:Cite news</ref> Experiments included administering LSD to CIA employees, military personnel, doctors, other government agents, prostitutes, mentally ill patients, and members of the general public to study their reactions, usually without the subjects' knowledge. The project was revealed in the US congressional Rockefeller Commission report in 1975. However, the extent of the experiments conducted under Project MKUltra are still mostly unknown, as acting CIA director Richard Helms destroyed many of the key documents related to MKUltra in 1973.<ref>Template:Cite book</ref>

In 1963, the Sandoz patents on LSD expired<ref name="henderson-glass"/> and the Czech company Spofa began to produce the substance.<ref name="Hofmann2009" /> Sandoz stopped the production and distribution in 1965.<ref name="Hofmann2009" />

Several figures, including Aldous Huxley, Timothy Leary, and Al Hubbard, had begun to advocate the consumption of LSD. LSD became central to the counterculture of the 1960s.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In the early 1960s the use of LSD and other hallucinogens was advocated by new proponents of consciousness expansion such as Leary, Huxley, Alan Watts and Arthur Koestler,<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> and according to L. R. Veysey they profoundly influenced the thinking of the new generation of youth.<ref>Template:Cite book</ref>

On October 24, 1968, possession of LSD was made illegal in the United States.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> The last FDA approved study of LSD in patients ended in 1980, while a study in healthy volunteers was made in the late 1980s. Legally approved and regulated psychiatric use of LSD continued in Switzerland until 1993.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In November 2020, Oregon became the first US state to decriminalize possession of small amounts of LSD after voters approved Ballot Measure 110.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Society and culture

Counterculture

By the mid-1960s, the youth countercultures in California, particularly in San Francisco, had widely adopted the use of hallucinogenic drugs, including LSD. The first major underground LSD factory was established by Owsley Stanley.<ref name=DeRogatispp8-9>Template:Cite book</ref> Around this time, the Merry Pranksters, associated with novelist Ken Kesey, organized the Acid Tests, events in San Francisco involving LSD consumption, accompanied by light shows and improvised music.<ref name=pc41>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name=Hicks2000p60>Template:Cite book</ref> Their activities, including cross-country trips in a psychedelically decorated bus and interactions with major figures of the beat movement, were later documented in Tom Wolfe's The Electric Kool-Aid Acid Test (1968).<ref name=Mann2009p87>Template:Cite book</ref>

In San Francisco's Haight-Ashbury neighborhood, the Psychedelic Shop was opened in January 1966 by brothers Ron and Jay Thelin to promote the safe use of LSD. This shop played a significant role in popularizing LSD in the area and establishing Haight-Ashbury as the epicenter of the hippie counterculture. The Thelins also organized the Love Pageant Rally in Golden Gate Park in October 1966, protesting against California's ban on LSD.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite journal</ref>

A similar movement developed in London, led by British academic Michael Hollingshead, who first tried LSD in America in 1961. After experiencing LSD and interacting with notable figures such as Aldous Huxley, Timothy Leary, and Richard Alpert, Hollingshead played a key role in the famous LSD research at Millbrook before moving to New York City for his experiments. In 1965, he returned to the UK and founded the World Psychedelic Center in Chelsea, London.<ref>Template:Cite book</ref>

Art and music

Art

Blotter art

{{#invoke:Labelled list hatnote|labelledList|Main article|Main articles|Main page|Main pages}}

File:LSD Tabs 50mcg.jpg

LSD tabs (50 mcg) featuring blotter art

Blotter art is an art form printed on perforated sheets of absorbent blotting paper infused with liquid LSD. The delivery method gained popularity following the banning of the hallucinogen LSD in the late 1960s. The use of graphics on blotter sheets originated as an underground art form in the early 1970s, sometimes to help identify the dosage, maker, or batch of LSD.

LSD art

{{#invoke:Labelled list hatnote|labelledList|Main article|Main articles|Main page|Main pages}}

File:Lsdfacecoloured.jpg

A drawing of a face, made under the effects of LSD. Dr. Oscar Janiger noted similarities between paintings made under the influence of the drug and those made by schizophrenics.

LSD art is any art or visual displays inspired by psychedelic experiences and hallucinations known to follow the ingestion of LSD, also known colloquially as acid).<ref name="Schmid_2015">Template:Cite journal</ref> Artists and scientists have been interested in the effect of LSD on drawing and painting since it first became available for legal use and general consumption.<ref>Template:Cite book</ref>

Music

File:Helix, v.2, no.6, Dec. 1, 1967 - DPLA - 85798bf5973acd2aa823cbc257dfae2a (page 1).jpg

Psychedelic art for the cover of an issue of underground counterculture newspaper Helix, 1967.

The influence of LSD in the realms of music and art became pronounced in the 1960s, especially through the Acid Tests and related events involving bands like the Grateful Dead, Jefferson Airplane, and Big Brother and the Holding Company. San Francisco-based artists such as Rick Griffin, Victor Moscoso, and Wes Wilson contributed to this movement through their psychedelic poster and album art. The Grateful Dead, in particular, became central to the culture of "Deadheads," with their music heavily influenced by LSD.<ref name=Jarnow/>

In the United Kingdom, Michael Hollingshead, reputed for introducing LSD to various artists and musicians like Storm Thorgerson, Donovan, Keith Richards, and members of the Beatles, played a significant role in the drug's proliferation in the British art and music scene. Despite LSD's illegal status from 1966, it was widely used by groups including the Beatles, the Rolling Stones, and the Moody Blues. Their experiences influenced works such as the Beatles' Sgt. Pepper's Lonely Hearts Club Band and Cream's Disraeli Gears, featuring psychedelic-themed music and artwork.<ref>Template:Cite magazine</ref>

Psychedelic music of the 1960s often sought to replicate the LSD experience, incorporating exotic instrumentation, electric guitars with effects pedals, and elaborate studio techniques. Artists and bands utilized instruments like sitars and tablas, and employed studio effects such as backward tapes, panning, and phasing.<ref>Template:Cite book</ref><ref>Template:Cite book</ref> Songs such as John Prine's "Illegal Smile" and the Beatles' "Lucy in the Sky with Diamonds" have been associated with LSD, although the latter's authors denied such claims.<ref name=Sheff>Template:Cite book</ref>Template:Page needed<ref name="life">Template:Cite magazine</ref>

Contemporary artists influenced by LSD include Keith Haring in the visual arts,<ref>Template:Cite book</ref> various electronic dance music creators,<ref>Template:Cite news</ref> and the jam band Phish.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> The 2018 Leo Butler play All You Need is LSD is inspired by the author's interest in the history of LSD.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Legal status

The United Nations Convention on Psychotropic Substances of 1971 mandates that signing parties, including the United States, Australia, New Zealand, and most of Europe, prohibit LSD. Enforcement of these laws varies by country. The convention allows medical and scientific research with LSD.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Australia

In Australia, LSD is classified as a Schedule 9 prohibited substance under the Poisons Standard (February 2017), indicating it may be abused or misused and its manufacture, possession, sale, or use should be prohibited except for approved research purposes.<ref name="Poisons Standard">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In Western Australia, the Misuse of Drugs Act 1981 provides guidelines for possession and trafficking of substances like LSD.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Canada

In Canada, LSD is listed under Schedule III of the Controlled Drugs and Substances Act. Unauthorized possession and trafficking of the substance can lead to significant legal penalties.<ref name="cdasa">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

United Kingdom

In the United Kingdom, LSD is a Class A drug under the Misuse of Drugs Act 1971, making unauthorized possession and trafficking punishable by severe penalties. The Runciman Report and Transform Drug Policy Foundation have made recommendations and proposals regarding the legal regulation of LSD and other psychedelics.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

United States

In the United States, LSD is classified as a Schedule I controlled substance under the Controlled Substances Act of 1970, making its manufacture, possession, and distribution illegal without a DEA license. The law considers LSD to have a high potential for abuse, no legitimate medical use, and to be unsafe even under medical supervision. The US Supreme Court case Neal v. United States (1995) clarified the sentencing guidelines related to LSD possession.<ref>Template:Cite court, originating from U.S. v. Neal, 46 F.3d 1405 (7th Cir. 1995)</ref>

Oregon decriminalized personal possession of small amounts of drugs, including LSD, in February 2021, and California has seen legislative efforts to decriminalize psychedelics.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Mexico

Mexico decriminalized the possession of small amounts of drugs, including LSD, for personal use in 2009. The law specifies possession limits and establishes that possession is not a crime within designated quantities.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Czech Republic

In the Czech Republic, possession of "amount larger than small" of LSD is criminalized, while possession of smaller amounts is a misdemeanor. The definition of "amount larger than small" is determined by judicial practice and specific regulations.<ref name="Cz expl rep">Template:Cite report</ref><ref>Template:Citation</ref>

Illicit supply chain

Production

File:LSDLabGlassware.jpg

Glassware seized by the DEA.

An active dose of LSD is very minute, allowing a large number of doses to be synthesized from a comparatively small amount of raw material. Twenty-five kilograms of precursor ergotamine tartrate can produce 5–6 kg of pure crystalline LSD; this corresponds to around 50–60 million doses at 100 μg. Because the masses involved are so small, concealing and transporting illicit LSD is much easier than smuggling cocaine, cannabis, or other illegal drugs.<ref name="DEA-pub">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Manufacturing LSD requires laboratory equipment and experience in the field of organic chemistry. It takes two to three days to produce 30 to 100 grams of pure compound. It is believed that LSD is not usually produced in large quantities, but rather in a series of small batches. This technique minimizes the loss of precursor chemicals in case a step does not work as expected.<ref name="DEA-pub"/> Ali Altaft, the lead chemist at the University of Okara, in Punjab, Pakistan, performed the synthesis of LSD on video.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Forms

LSD is produced in crystalline form and is then mixed with excipients or redissolved for production in ingestible forms. Liquid solution is either distributed in small vials or, more commonly, sprayed onto or soaked into a distribution medium. Historically, LSD solutions were first sold on sugar cubes, but practical considerationsTemplate:Clarification needed forced a change to tablet form. Appearing in 1968 as an orange tablet measuring about 6 mm across, "Orange Sunshine" acid was the first largely available form of LSD after its possession was made illegal. Tim Scully, a prominent chemist, made some of these tablets, but said that most "Sunshine" in the USA came by way of Ronald Stark, who imported approximately thirty-five million doses from Europe.<ref name=Stafford1992>Template:Cite book</ref>

Over some time, tablet dimensions, weight, shape and concentration of LSD evolved from large (4.5–8.1 mm diameter), heavyweight (≥150 μg), round, high concentration (90–350 μg/tab) dosage units to small (2.0–3.5 mm diameter) lightweight (as low as 4.7 μg/tab), variously shaped, lower concentration (12–85 μg/tab, average range 30–40 μg/tab) dosage units. LSD tablet shapes have included cylinders, cones, stars, spacecraft, and heart shapes. The smallest tablets became known as "Microdots."<ref name=Laing2003>Template:Cite book</ref>

After tablets came "computer acid" or "blotter paper LSD," typically made by dipping a preprinted sheet of blotting paper into an LSD/water/alcohol solution.<ref name=Stafford1992/><ref name=Laing2003/> More than 200 types of LSD tablets have been encountered since 1969 and more than 350 blotter paper designs have been observed since 1975.<ref name=Laing2003/> About the same time as blotter paper LSD came "Windowpane" (AKA "Clearlight"), which contained LSD inside a thin gelatin square a quarter of an inch (6 mm) across.<ref name=Stafford1992/> LSD has been sold under a wide variety of often short-lived and regionally restricted street names including Acid, Trips, Uncle Sid, Blotter, Lucy, Alice and doses, as well as names that reflect the designs on the sheets of blotter paper.<ref name="erowid-faq"/><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Authorities have encountered the drug in other forms—including powder or crystal, and capsule.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Blotters

Blotter art designs printed on blotter paper can serve to identify dosage strengths, different batches, or makers.<ref name="Sfetcu">Template:Cite book</ref>

On the other hand, blotters without art may be considered safer by some, since there is no guarantee that the printer ink used in clandestine production is edible or non-toxic for long-term exposure, and it is also possible for unscrupulous dealers to mimic reputable blotter art designs in order to boost sales.

{{#invoke:Gallery|gallery}}

Distribution

LSD manufacturers and traffickers in the United States can be categorized into two groups: A few large-scale producers, and an equally limited number of small, clandestine chemists, consisting of independent producers who, operating on a comparatively limited scale, can be found throughout the country.<ref>Template:Cite book</ref><ref>Template:Cite book</ref>

As a group, independent producers are of less concern to the Drug Enforcement Administration than the large-scale groups because their product reaches only local markets.<ref name="LSD: The Drug"/>

Many LSD dealers and chemists describe a religious or humanitarian purpose that motivates their illicit activity. Nicholas Schou's book Orange Sunshine: The Brotherhood of Eternal Love and Its Quest to Spread Peace, Love, and Acid to the World describes one such group, the Brotherhood of Eternal Love. The group was a major American LSD trafficking group in the late 1960s and early 1970s.<ref>Template:Cite book</ref>

In the second half of the 20th century, dealers and chemists loosely associated with the Grateful Dead like Owsley Stanley, Nicholas Sand, Karen Horning, Sarah Maltzer, "Dealer McDope," and Leonard Pickard played an essential role in distributing LSD.<ref name=Jarnow>Template:Cite book</ref>

Template:Anchor Mimics

File:Docpsychadelic.jpg

LSD blotter acid mimic actually containing DOC.

File:Lysergic.JPG

Different blotters which could possibly be mimics.

Since 2005, law enforcement in the United States and elsewhere has seized several chemicals and combinations of chemicals in blotter paper which were sold as LSD mimics, including DOB,<ref name="microgram october 2005">Template:Cite journal</ref><ref name="microgram november 2006">Template:Cite journal</ref> a mixture of DOC and DOI,<ref name="microgram march 2008">Template:Cite journal</ref> 25I-NBOMe,<ref name="ACMD Report">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> and a mixture of DOC and DOB.<ref name="microgram march 2009">Template:Cite journal</ref> Many mimics are toxic in comparatively small doses, or have extremely different safety profiles. Many street users of LSD are often under the impression that blotter paper which is actively hallucinogenic can only be LSD because that is the only chemical with low enough doses to fit on a small square of blotter paper. While it is true that LSD requires lower doses than most other hallucinogens, blotter paper is capable of absorbing a much larger amount of material. The DEA performed a chromatographic analysis of blotter paper containing 2C-C which showed that the paper contained a much greater concentration of the active chemical than typical LSD doses, although the exact quantity was not determined.<ref name="microgram november 2005">Template:Cite journal</ref> Blotter LSD mimics can have relatively small dose squares; a sample of blotter paper containing DOC seized by Concord, California police had dose markings approximately 6 mm apart.<ref name="microgram december 2007">Template:Cite journal</ref> Several deaths have been attributed to 25I-NBOMe.<ref name="Erowid25I-NBOMe">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="NY Daily news">Template:Cite news</ref><ref name="Ireland injuries">Template:Cite news</ref><ref name="ACMD Report2">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Notable individuals

Some notable individuals have commented publicly on their experiences with LSD.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Some of these comments date from the era when it was legally available in the US and Europe for non-medical uses, and others pertain to psychiatric treatment in the 1950s and 1960s. Still others describe experiences with illegal LSD, obtained for philosophic, artistic, therapeutic, spiritual, or recreational purposes.

• W. H. Auden, the poet, said, "I myself have taken mescaline once and L.S.D. once. Aside from a slight schizophrenic dissociation of the I from the Not-I, including my body, nothing happened at all."<ref>Template:Cite journal</ref> He also said, "LSD was a complete frost. … What it does seem to destroy is the power of communication. I have listened to tapes done by highly articulate people under LSD, for example, and they talk absolute drivel. They may have seen something interesting, but they certainly lose either the power or the wish to communicate."<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref> He also said, "Nothing much happened but I did get the distinct impression that some birds were trying to communicate with me."<ref>Template:Cite news</ref>

• James Cameron, the Canadian filmmaker, has said he experimented with LSD during his college years.<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref>

• Daniel Ellsberg, an American peace activist, says he has had several hundred experiences with psychedelics.<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref>

• Richard Feynman, a notable physicist at California Institute of Technology, tried LSD during his professorship at Caltech. Feynman largely sidestepped the issue when dictating his anecdotes; he mentions it in passing in the "O Americano, Outra Vez" section.<ref>Template:Cite book</ref><ref>Template:Cite book</ref>
• Jerry Garcia stated in a July 3, 1989 interview for Relix Magazine, in response to the question "Have your feelings about LSD changed over the years?," "They haven't changed much. My feelings about LSD are mixed. It's something that I both fear and that I love at the same time. I never take any psychedelic, have a psychedelic experience, without having that feeling of, "I don't know what's going to happen." In that sense, it's still fundamentally an enigma and a mystery."<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref>

• Bill Gates implied in an interview with Playboy that he tried LSD during his youth.<ref>Template:Cite magazine</ref>
• Aldous Huxley, author of Brave New World, became a user of psychedelics after moving to Hollywood. He was at the forefront of the counterculture's use of psychedelic drugs, which led to his 1954 work The Doors of Perception. Dying from cancer, he asked his wife on 22 November 1963 to inject him with 100 μg of LSD. He died later that day.<ref name=OpenCulture>Template:Cite news</ref>
• Steve Jobs, co-founder and former CEO of Apple Inc., said, "Taking LSD was a profound experience, one of the most important things in my life."<ref>Template:Cite news</ref>
• Ernst Jünger, German writer and philosopher, throughout his life had experimented with drugs such as ether, cocaine, and hashish; and later in life he used mescaline and LSD. These experiments were recorded comprehensively in Annäherungen (1970, Approaches). The novel Besuch auf Godenholm (1952, Visit to Godenholm) is clearly influenced by his early experiments with mescaline and LSD. He met with LSD inventor Albert Hofmann and they took LSD together several times. Hofmann's memoir LSD, My Problem Child describes some of these meetings.<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref>

• In a 2004 interview, Paul McCartney said that The Beatles' songs "Day Tripper" and "Lucy in the Sky with Diamonds" were inspired by LSD trips.<ref name=Sheff/>Template:Rp Nonetheless, John Lennon consistently stated over the course of many years that the fact that the initials of "Lucy in the Sky with Diamonds" spelled out L-S-D was a coincidence (he stated that the title came from a picture drawn by his son Julian) and that the band members did not notice until after the song had been released, and Paul McCartney corroborated that story.<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref> John Lennon, George Harrison, and Ringo Starr also used the drug, although McCartney cautioned that "it's easy to overestimate the influence of drugs on the Beatles' music."<ref name="weeklystandard">Template:Cite magazine</ref>

• Michel Foucault had an LSD experience with Simeon Wade in Death Valley and later wrote "it was the greatest experience of his life, and that it profoundly changed his life and his work."<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref><ref>Template:Cite news Wade: "We fell silent to listen to Stockhausen's Songs of Youth. Zabriskie Point was filled with the sound of a kindergarten playground overlaid with electric tonalities. Kontakte followed. Glissandos bounced off the stars, which glowed like incandescent pinballs. Foucault turned to Michael and said this is the first time he really understood what Stockhausen had achieved".</ref> According to Wade, as soon as he came back to Paris, Foucault scrapped the second History of Sexuality's manuscript, and totally rethought the whole project.<ref>Template:Cite book In a letter to Wade, dated 16 September 1978, Foucault authorised the book's publication and added: "How could I not love you?"</ref>

• Kary Mullis is reported to credit LSD with helping him develop DNA amplification technology, for which he received the Nobel Prize in Chemistry in 1993.<ref>Template:Cite magazine</ref>
• Carlo Rovelli, an Italian theoretical physicist and writer, has credited his use of LSD with sparking his interest in theoretical physics.<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref>

• Oliver Sacks, a neurologist famous for writing best-selling case histories about his patients' disorders and unusual experiences, talks about his own experiences with LSD and other perception altering chemicals, in his book, Hallucinations.<ref>Template:Cite book</ref>
• Alexander Shulgin, American chemist, told Albert Hofmann that he preferred LSD to 2C-B.
• Matt Stone and Trey Parker, creators of the TV series South Park, claimed to have shown up at the 72nd Academy Awards, at which they were nominated for Best Original Song, under the influence of LSD.<ref>{{#invoke:citation/CS1|citation

|CitationClass=web }}</ref>

Research

It was initially explored for psychiatric use due to its structural similarity to serotonin and safety profile.<ref name="Nichols2018a" />

In the United States, the earliest research began in the 1950s. Albert Kurland and his colleagues published research on LSD's therapeutic potential to treat schizophrenia. In Canada, Humphry Osmond and Abram Hoffer completed LSD studies as early as 1952.<ref>Template:Cite journal</ref> By the 1960s, controversies surrounding "hippie" counterculture began to deplete institutional support for continued studies.

Currently, several organizations—including the Beckley Foundation, MAPS, Heffter Research Institute and the Albert Hofmann Foundation—exist to fund, encourage and coordinate research into the medicinal and spiritual uses of LSD and related psychedelics.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> New clinical LSD experiments in humans started in 2009 for the first time in 35 years.<ref name="new research">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> As it is illegal in many areas of the world, potential medical uses are difficult to study.<ref name=Nutt2009/>

In 2001 the United States Drug Enforcement Administration stated that LSD "produces no aphrodisiac effects, does not increase creativity, has no lasting positive effect in treating alcoholics or criminals, does not produce a "model psychosis", and does not generate immediate personality change."<ref name="LSD: The Drug"/> More recently, experimental uses of LSD have included the treatment of alcoholism,<ref name=":0">Template:Cite journal</ref> pain and cluster headache relief,<ref name="PassieHalpernStrichtenoth2008" /><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> and prospective studies on depression.<ref>Template:Cite journal</ref>

A 2020 meta-review indicated possible positive effects of LSD in reducing psychiatric symptoms, mainly in cases of alcoholism.<ref>Template:Cite journal</ref> There is evidence that psychedelics induce molecular and cellular adaptations related to neuroplasticity and that these could potentially underlie therapeutic benefits.<ref name="pmid36123427">Template:Cite journal</ref><ref name="pmid35060714">Template:Cite journal</ref>

Psychedelic therapy

In the 1950s and 1960s, LSD was used in psychiatry to enhance psychotherapy, known as psychedelic therapy. Some psychiatrists, such as Ronald A. Sandison, who pioneered its use at Powick Hospital in England, believed LSD was especially useful at helping patients to "unblock" repressed subconscious material through other psychotherapeutic methods,<ref>Cohen, S. (1959). "The therapeutic potential of LSD-25". A Pharmacologic Approach to the Study of the Mind, p. 251–258.</ref> and also for treating alcoholism.<ref>Template:Cite journal Via {{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite journal</ref> One study concluded, "The root of the therapeutic value of the LSD experience is its potential for producing self-acceptance and self-surrender,"<ref name="Use of d-lysergic acid diethylamide"/> presumably by forcing the user to face issues and problems in that individual's psyche.

Two recent reviews concluded that conclusions drawn from most of these early trials are unreliable due to serious methodological flaws. These include the absence of adequate control groups, lack of follow-up, and vague criteria for therapeutic outcome. In many cases, studies failed to convincingly demonstrate whether the drug or the therapeutic interaction was responsible for any beneficial effects.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

In recent years, organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS) have renewed clinical research of LSD.<ref name="new research"/>

It has been proposed that LSD be studied for use in the therapeutic setting, particularly in anxiety.<ref name=":5"/><ref name=":6"/><ref name="clinicalLSD">Template:Cite journal</ref><ref>Template:Cite news</ref> In 2024, the FDA designated a form of LSD as a breakthrough therapy to treat generalized anxiety disorder which is being developed by MindMed.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Other uses

In the 1950s and 1960s, some psychiatrists (e.g., Oscar Janiger) explored the potential effect of LSD on creativity. Experimental studies attempted to measure the effect of LSD on creative activity and aesthetic appreciation.<ref name="PMID6054248"/><ref name="PMID18562421">Template:Cite journal</ref><ref name="PMID2723891">Template:Cite journal</ref><ref name="Stafford-Golightly">Template:Cite book</ref> In 1966 Dr. James Fadiman conducted a study with the central question "How can psychedelics be used to facilitate problem solving?" This study attempted to solve 44 different problems and had 40 satisfactory solutions when the FDA banned all research into psychedelics. LSD was a key component of this study.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite book</ref>

Since 2008 there has been ongoing research into using LSD to alleviate anxiety for terminally ill cancer patients coping with their impending deaths.<ref name=":5" /><ref name="new research"/><ref>Template:Cite news</ref>

A 2012 meta-analysis found evidence that a single dose of LSD in conjunction with various alcoholism treatment programs was associated with a decrease in alcohol abuse, lasting for several months, but no effect was seen at one year. Adverse events included seizure, moderate confusion and agitation, nausea, vomiting, and acting in a bizarre fashion.<ref name="Lysergic acid diethylamide LSD fo"/>

LSD has been used as a treatment for cluster headaches with positive results in some small studies.<ref name="PassieHalpernStrichtenoth2008" />

LSD is a potent psychoplastogen, a compound capable of promoting rapid and sustained neural plasticity that may have wide-ranging therapeutic benefit.<ref name=Ly2018>Template:Cite journal</ref> LSD has been shown to increase markers of neuroplasticity in human brain organoids and improve memory performance in human subjects.<ref>Template:Cite news</ref>

LSD may have analgesic properties related to pain in terminally ill patients and phantom pain and may be useful for treating inflammatory diseases including rheumatoid arthritis.<ref name=lsdpain>Template:Cite journal</ref>

Further reading

• Template:Cite book

External links

• {{#invoke:citation/CS1|citation

|CitationClass=web }}

Documentaries

• Hofmann's Potion Template:Webarchive a documentary on the origins of LSD, 2002
• Inside LSD National Geographic Channel, 2009
• How to Change Your Mind Template:Webarchive Netflix docuseries, 2022